Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITIL-168 + cyclophosphamide + fludarabine + aldesleukin
- Development stage
- Unknown
- Lead developer
- Instil Bio
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous
01
Overview
**ITIL-168 + cyclophosphamide + fludarabine + aldesleukin** is a multi-component regimen used in experimental protocols for advanced melanoma and other solid tumors. **ITIL-168** is an autologous tumor-infiltrating lymphocyte (TIL) therapy, manufactured from a patient's own tumor cells, isolated and expanded ex vivo for reinfusion[1][3][4]. Before TIL infusion, patients receive *lymphodepleting chemotherapy* with **cyclophosphamide** and **fludarabine** to reduce endogenous lymphocytes and enhance engraftment of the infused TILs. After TIL infusion, **aldesleukin** (recombinant interleukin-2, IL-2) is administered to stimulate T-cell proliferation and support anti-tumor immune activity[1][2][3][4]. The regimen aims to achieve durable tumor remission through adoptive cell transfer immunotherapy. ITIL-168 is being developed by Instil Bio primarily for melanoma, and is studied in various Phase 1 and 2 clinical trials[1][2][3][4].
- Other names
- tumor-infiltrating lymphocyte therapy + cyclophosphamide + fludarabine + IL-2
02
Targets
DNAIL-2R (Interleukin-2/interleukin-15 receptor complex)MAGEA8 (Melanoma-associated antigen 8)
Beyond the preview
Go deeper on ITIL-168 + cyclophosphamide + fludarabine + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITIL-168 + cyclophosphamide + fludarabine + aldesleukin.